Functional analysis of CD44 variants and xCT in canine tumours.
Amino Acid Transport Systems, Acidic
/ antagonists & inhibitors
Animals
Biomarkers, Tumor
/ metabolism
Breast Neoplasms
Dog Diseases
/ genetics
Dogs
Female
Gene Expression Regulation, Neoplastic
Glutathione
/ metabolism
Hyaluronan Receptors
/ genetics
Protein Isoforms
Reactive Oxygen Species
/ metabolism
Sulfasalazine
/ pharmacology
Up-Regulation
CD44
canine
oxidative stress
radiation
xCT
Journal
Veterinary medicine and science
ISSN: 2053-1095
Titre abrégé: Vet Med Sci
Pays: England
ID NLM: 101678837
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
revised:
12
10
2020
received:
19
02
2020
accepted:
02
11
2020
pubmed:
20
11
2020
medline:
21
10
2021
entrez:
19
11
2020
Statut:
ppublish
Résumé
The cell surface glycoprotein CD44 has various types of splicing variants, which contribute to its multiple distinct cellular functions. Recently, it was reported that the CD44v8-10 isoform interacts with the system Xc(-) transporter-related protein (xCT), and inhibits the accumulation of reactive oxygen species by promoting the synthesis of the antioxidant glutathione in human tumour cells. In this study, we investigated the expression and function of CD44 variants and xCT in canine tumours. From semi-quantitative reverse transcription polymerase chain reaction analysis, the mRNA expression of the CD44v8-10 isoform was observed in canine tumour tissues as well as human cases. The overexpression of CD44v8-10 may promote the synthesis of glutathione and enhance the resistance to radiation of canine breast tumour cells. Furthermore, canine xCT mRNA expression was significantly upregulated in the canine breast tumour tissues as compared to the normal tissues surrounding the tumours. To investigate the function of canine xCT, we treated canine tumour cells with the xCT inhibitor sulfasalazine. Consequently, the sulfasalazine-treated cells were more sensitive to oxidative stress than the non-treated cells. Taken together, these results suggested that CD44v8-10 and xCT play important roles in the therapy resistance of canine tumours as well as human tumours.
Identifiants
pubmed: 33210459
doi: 10.1002/vms3.397
pmc: PMC8025623
doi:
Substances chimiques
Amino Acid Transport Systems, Acidic
0
Biomarkers, Tumor
0
Hyaluronan Receptors
0
Protein Isoforms
0
Reactive Oxygen Species
0
Sulfasalazine
3XC8GUZ6CB
Glutathione
GAN16C9B8O
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
577-585Informations de copyright
© 2020 The Authors Veterinary Medicine and Science Published by John Wiley & Sons Ltd.
Références
Int J Oncol. 2017 Sep;51(3):771-780
pubmed: 28677740
Cell Death Differ. 2012 May;19(5):847-58
pubmed: 22095285
Vet Pathol. 2011 Sep;48(5):1029-34
pubmed: 21245282
Am J Vet Res. 2018 Sep;79(9):961-969
pubmed: 30153061
J Biol Chem. 2009 Jan 9;284(2):1106-15
pubmed: 19017641
Cancer Sci. 2019 Apr;110(4):1431-1441
pubmed: 30719824
Nat Commun. 2012 Jun 06;3:883
pubmed: 22673910
J Vet Med Sci. 1999 Apr;61(4):361-7
pubmed: 10342286
J Clin Invest. 2011 Mar;121(3):1064-74
pubmed: 21393860
Biochem Biophys Res Commun. 2018 Dec 9;507(1-4):426-432
pubmed: 30448176
Oncol Lett. 2018 May;15(5):7987-7992
pubmed: 29755597
Mol Pathol. 1999 Aug;52(4):189-96
pubmed: 10694938
Cancer Res. 2013 Mar 15;73(6):1855-66
pubmed: 23319806
J Vet Med Sci. 2001 Sep;63(9):1031-4
pubmed: 11642274
Cancer Res. 2012 Jul 1;72(13):3414-23
pubmed: 22552294
Cancer Res. 2005 Aug 15;65(16):7446-54
pubmed: 16103098
Oncogene. 2013 Oct 31;32(44):5191-8
pubmed: 23334333
Cancer Lett. 2015 Nov 1;368(1):88-96
pubmed: 26254540
Int J Cancer. 2015 Dec 1;137(11):2566-77
pubmed: 26077342
J Biol Chem. 2002 Nov 22;277(47):44765-71
pubmed: 12235164
Immunogenetics. 1994;40(6):437-44
pubmed: 7525471
Cancer Sci. 2018 Sep;109(9):2801-2810
pubmed: 29981246
BMC Cancer. 2015 Nov 16;15:903
pubmed: 26572077
J Vet Med Sci. 2004 Nov;66(11):1437-40
pubmed: 15585963
Nat Rev Cancer. 2011 Apr;11(4):254-67
pubmed: 21390059
Diagn Pathol. 2014 Apr 08;9:79
pubmed: 24708709
J Vet Med Sci. 1994 Dec;56(6):1167-9
pubmed: 7696411
Leukemia. 2001 Oct;15(10):1633-40
pubmed: 11587223
Oncol Lett. 2017 Jul;14(1):427-432
pubmed: 28693187
Nat Rev Mol Cell Biol. 2003 Jan;4(1):33-45
pubmed: 12511867
Br J Cancer. 2013 Jul 23;109(2):379-86
pubmed: 23778530
Vet Comp Oncol. 2016 Sep;14(3):e93-e101
pubmed: 25070729
J Cell Physiol. 2008 Jun;215(3):593-602
pubmed: 18181196
Cancer Cell. 2011 Mar 8;19(3):387-400
pubmed: 21397861
BMC Vet Res. 2013 Jun 13;9:116
pubmed: 23758893
Cancer Med. 2019 Feb;8(2):773-782
pubmed: 30636370
Sci Rep. 2018 Nov 19;8(1):16985
pubmed: 30451890
Front Oncol. 2017 Dec 21;7:319
pubmed: 29312889
Oncogenesis. 2017 Oct 9;6(10):e389
pubmed: 28991261
Vet Immunol Immunopathol. 2014 May 15;159(1-2):91-6
pubmed: 24629892
Vet Med Sci. 2021 Mar;7(2):577-585
pubmed: 33210459
Vet Immunol Immunopathol. 2014 Oct 15;161(3-4):132-40
pubmed: 25146881
BMC Cancer. 2015 Apr 07;15:228
pubmed: 25884842